Harmonizing body surface area assessments between the Eczema Area and Severity Index, SCORing Atopic Dermatitis, and handprint methods utilizing one shared measurement-A proposal to improve efficiency and reduce error in atopic dermatitis trials
Date: 2024-02-22 Authors: M E Jacobson 1, R S Seshadri1, R Bissonnette2, A S Paller3, S Weidinger4, J P Thyssen5, B Hester1, E L Simpson1 Category: Dermatitis Read more on pubmed
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis
Date: 2024-02-08 Authors: Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K Category: Psoriasis Background:Â The use of monoclonal antibodies has changed the treatment of several immune-mediated inflammatory diseases, including psoriasis. However, these large proteins must be administered by injection. JNJ-77242113 […]
Psychometric validation of the Psoriasis Symptom Scale, Functional Assessment of Chronic Illness Therapy-Fatigue and pain-Visual Analogue Scale in patients with generalized pustular psoriasis.
Date: 2024-02-09 Authors:Burden AD, Bissonnette R, Anatchkova M, Budhiarso I, Skalicky AM, Liberato ACS, Hu N, Thoma C, Gloede T, Kohlmann T, Lebwohl MG Category: Psoriasis Background:Â Generalized pustular psoriasis (GPP) is a rare, chronic, inflammatory skin disease associated with considerable patient burden. The Psoriasis Symptom Scale (PSS), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) and […]
Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
Date: 2024-01-31 Authors: Simpson EL, Bissonnette R, Chiesa Fuxench ZC, Kallender H, Sturm D, Ren H, Stein Gold LF Category: Dermatitis Purpose:Â Ruxolitinib (selective Janus kinase [JAK] 1 and JAK2 inhibitor) cream demonstrated efficacy and safety in patients with atopic dermatitis (AD) in the phase 3 TRuE-AD studies. In TRuE-AD1/TRuE-AD2 (NCT03745638/NCT03745651), adults and adolescents with mild […]
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis
Date: 2023-12-18 Authors: Guttman-Yassky E, Facheris P, Gomez-Arias PJ, Del Duca E, Da Rosa JC, Weidinger S, Bissonnette R, Armstrong AW, Seneschal J, Eyerich K, Estrada YD, Bose SN, Xu D, Chen A, Tatulych S, GĂŒler E, Chan G, Page KM, Kerkmann U Category: Dermatitis Background:Â This is the first report on the effects of abrocitinib, […]
Eligibility Criteria for Active Ulcerative Pyoderma Gangrenosum (PG) in Clinical Trials: A Delphi Consensus on Behalf of the Understanding PG: Review and Assessment of Disease Effects (UPGRADE) Group
Date:2023-12-16 Authors: Kamal K, Xia E, Li SJ, Alavi A, Cogen AL, Firooz A, Marzano AV, Kaffenberger BH, Sibbald C, Fernandez AP, Callen JP, Dissemond J, Renato V Gontijo J, Shams K, Gerbens LA, French LE, Gould LJ, Bissonnette R, Shaigany S, Tolkachjov S, Yamamoto T, Wei-Ting Huang W, Ortega-Loayza AG, Mostaghimi A Category: Other […]
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Date: 2023-11-27 Authors: Gooderham MJ, Bissonnette R, Kalia S, Papp KA, Guenther LC, Gulliver WP, Ho V, Shear NH, Vender R, Gniadecki R, Prajapati VH, Turchin I, Langholff W, Parnell K, Simpson SD, Abbarin N, Lakhani O, Alhusayen R Category:Psoriasis Background:Â The Psoriasis Longitudinal Assessment and Registry (PSOLAR) is a global, prospective, longitudinal, disease-based registry. It […]
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 study
Date: 2023-11-27 Authors: Bissonnette R, DuBois J, Facheris P, Del Duca E, Kim M, Correa Da Rosa J, Trujillo DL, Bose S, Pagan AD, Wustrow D, Brockstedt DG, Wong B, Kassner PD, Jankicevic J, Ho W, Cheng LE, Guttman-Yassky E Category: Dermatitis Background:Â RPT193 is an orally administered small molecule antagonist of the human C-C motif […]
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council
Date: 2023-11-27 Authors: Bissonnette R, Simpson E, Eichenfield LF, Guttman-Yassky E, Silverberg JI, Beck LA, Mija L, Thyssen JP, Bieber T, Kabashima K, Siegfried E, Stingl G, van de Kerkhof P, Yosipovitch G, Paul C, Paller AS Category: Dermatitis Read more on pubmed
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Date:2023-09-20 Authors: Burden AD, Bissonnette R, Navarini AA, Murakami M, Morita A, Haeufel T, Ye B, Baehner F, Terui T Category:Psoriasis Introduction:Â We evaluated the anti-interleukin-36 receptor antibody spesolimab in patients with moderate-to-severe palmoplantar pustulosis (PPP). Read more on pubmed
